ATE462710T1 - Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert - Google Patents

Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Info

Publication number
ATE462710T1
ATE462710T1 AT03791618T AT03791618T ATE462710T1 AT E462710 T1 ATE462710 T1 AT E462710T1 AT 03791618 T AT03791618 T AT 03791618T AT 03791618 T AT03791618 T AT 03791618T AT E462710 T1 ATE462710 T1 AT E462710T1
Authority
AT
Austria
Prior art keywords
disease
crohn
fibrostenosis
fibrostenosing
nod2
Prior art date
Application number
AT03791618T
Other languages
English (en)
Inventor
Maria Abreu
Kent Taylor
Jerome Rotter
Huiying Yang
Kazuhito Sugimura
Stephan Targan
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ATE462710T1 publication Critical patent/ATE462710T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03791618T 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert ATE462710T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40739102P 2002-08-30 2002-08-30
US10/356,736 US20040053263A1 (en) 2002-08-30 2003-01-30 Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
PCT/US2003/023926 WO2004020968A2 (en) 2002-08-30 2003-07-30 Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease

Publications (1)

Publication Number Publication Date
ATE462710T1 true ATE462710T1 (de) 2010-04-15

Family

ID=31981139

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03791618T ATE462710T1 (de) 2002-08-30 2003-07-30 Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert

Country Status (7)

Country Link
US (2) US20040053263A1 (de)
EP (1) EP1556405B1 (de)
JP (2) JP4606877B2 (de)
AT (1) ATE462710T1 (de)
AU (1) AU2003263834A1 (de)
DE (1) DE60331941D1 (de)
WO (1) WO2004020968A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828132B2 (en) * 2001-03-01 2004-12-07 Ultra Biotech Limited Biological fertilizer compositions comprising garbage
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
US7662569B2 (en) * 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
US7592150B2 (en) * 2003-12-03 2009-09-22 Glycominds, Ltd Method for diagnosing diseases based on levels of anti-glycan antibodies
US20060205022A1 (en) * 2003-12-03 2006-09-14 Nir Dotan Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease
CA2546837A1 (en) * 2003-12-03 2005-06-16 Glycominds Ltd. Method for diagnosing diseases based on levels of anti-glycan antibodies
PL1730315T3 (pl) * 2004-03-27 2010-03-31 Klein Hanns Georg Polimorfizmy w genie NOD2/CARD15
WO2005115135A2 (en) * 2004-04-09 2005-12-08 The Regents Of The University Of California Mouse model of crohn’s disease and a method to develop specific therapeutics
US10544459B2 (en) * 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US12110555B2 (en) 2004-12-08 2024-10-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
EP2049691A4 (de) * 2006-07-26 2010-06-16 Genizon Biosciences Inc Suszeptibilitätsgen für morbus crohn
EP2102651A4 (de) * 2006-11-30 2010-11-17 Navigenics Inc Genanalysesysteme und -verfahren
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
WO2009069007A2 (en) * 2007-11-30 2009-06-04 Glycominds, Ltd. Composition and method for prediction of complicated disease course and surgeries in crohn's disease
WO2009143278A2 (en) * 2008-05-20 2009-11-26 Cedars-Sinai Medical Center Methods of diagnosing and characterizing cannabinoid signaling in crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
WO2010120814A1 (en) 2009-04-14 2010-10-21 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
WO2011060098A1 (en) 2009-11-10 2011-05-19 Prometheus Laboratories Inc. Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
WO2011088306A1 (en) * 2010-01-15 2011-07-21 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose crohn's disease
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
CN103502815B (zh) 2011-02-17 2015-09-23 雀巢产品技术援助有限公司 检测针对抗-TNFα药物的自身抗体的测定法
EP3330711A1 (de) * 2011-03-25 2018-06-06 Cedars-Sinai Medical Center Verfahren zur diagnose und behandlung intestinaler granulome und niedriger knochendichte bei entzündlichen darmerkrankungen
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
WO2013059732A1 (en) 2011-10-21 2013-04-25 Nestec S.A. Methods for improving inflammatory bowel disease diagnosis
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2014165825A2 (en) 2013-04-04 2014-10-09 President And Fellows Of Harvard College Therapeutic uses of genome editing with crispr/cas systems
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
MX2017012407A (es) 2015-03-27 2018-03-07 Harvard College Celulas t modificadas y métodos para hacer y usar las mismas.
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法
WO2018195129A1 (en) 2017-04-17 2018-10-25 University Of Maryland, College Park Embryonic cell cultures and methods of using the same
CA3124970A1 (en) * 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157053B2 (ja) * 1992-09-16 2001-04-16 ティーディーケイ株式会社 Ｄｎａ作用物質の結合様式特定方法
EP0615129B1 (de) * 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Verfahren zum selektiven Nachweis von perinuklearen anti-neutrophilen cytoplasmischen Antikörpern bei ulzerativen Kolitis oder primärer sclerotischer Cholangitis
US5830675A (en) * 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
AU2438397A (en) * 1996-04-12 1997-11-07 Cedars-Sinai Medical Center Methods of determining the risk of pouchitis development
US6074835A (en) * 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5916748A (en) * 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US5968741A (en) * 1997-04-11 1999-10-19 Cedars-Sinai Medical Center Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
JP2001269196A (ja) * 2000-03-24 2001-10-02 Hamamatsu Photonics Kk 被検体核酸の定量方法、および被検体核酸の分子数の計数方法
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
US20040053263A1 (en) * 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

Also Published As

Publication number Publication date
US20040053263A1 (en) 2004-03-18
JP2006500016A (ja) 2006-01-05
JP4606877B2 (ja) 2011-01-05
WO2004020968A2 (en) 2004-03-11
AU2003263834A1 (en) 2004-03-19
WO2004020968A3 (en) 2004-08-26
EP1556405A4 (de) 2007-01-10
AU2003263834A8 (en) 2004-03-19
EP1556405A2 (de) 2005-07-27
US7790370B2 (en) 2010-09-07
DE60331941D1 (de) 2010-05-12
US20070072180A1 (en) 2007-03-29
JP2011015686A (ja) 2011-01-27
EP1556405B1 (de) 2010-03-31

Similar Documents

Publication Publication Date Title
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
CA2282746A1 (en) Prediction of coronary artery disease
DK1421215T3 (da) Fremgangsmåder til evaluering af patologiske tilstande under anvendelse af ekstracellulært RNA
WO2003089897A3 (en) Diagnosis and treatment of vascular disease
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
Stone et al. Selection of acute stroke patients for treatment of visual neglect.
Aaltonen et al. Motives for physical activity in older men and women: A twin study using accelerometer‐measured physical activity
DE69231595D1 (de) Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
Meyer et al. Brief report: spatial heterogeneity of systemic sclerosis in France: high prevalence in the Northeast Region
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
SE0300959D0 (sv) Methods for predicting therapeutic response to agents acting on the growth hormone receptor
De Haes et al. Patient participation and decision control: are patient autonomy and well-being associated?
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
AU2003233292A8 (en) Protein c polymorphisms
DE60229513D1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
Saleh et al. Predicting which patients with cirrhosis will develop overt hepatic encephalopathy: Beyond psychometric testing
WO2003104812A3 (en) DIAGNOSIS ASSAY FOR ALZHEIMER'S DISEASE BASED ON THE DETERMINATION OF THE HA DOLLAR G (B) 42 RATE: HA DOLLAR G (B) 40
EP1722225A4 (de) Verfahren zur diagnose der immunität wiederkehrenden spontanen schwangerschaftsabbruchs sowie verfahren zur behandlung und überwachung
NO20002176D0 (no) Diagnostikk og terapi av kronisk obstruktiv luftveissykdom
GB0223655D0 (en) Method of diagnosis
Yang et al. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred
WO2003007801A3 (en) Diagnosis and treatment of vascular disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties